Dorman Products (NASDAQ:DORM – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Roth Mkm in a note issued to investors on Monday, Benzinga reports. They currently have a $153.00 price target on the auto parts company’s stock, up from their previous price target of $126.00. Roth Mkm’s target price would indicate a potential upside of 14.84% from the company’s current price.
Separately, CJS Securities initiated coverage on Dorman Products in a report on Friday, September 13th. They set an “outperform” rating and a $134.00 price objective on the stock. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $125.67.
View Our Latest Stock Report on Dorman Products
Dorman Products Stock Up 4.3 %
Dorman Products (NASDAQ:DORM – Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The auto parts company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.53 by $0.43. Dorman Products had a return on equity of 17.15% and a net margin of 9.43%. The business had revenue of $503.77 million for the quarter, compared to analysts’ expectations of $509.54 million. During the same quarter in the previous year, the business posted $1.40 EPS. Dorman Products’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, research analysts forecast that Dorman Products will post 6.15 EPS for the current fiscal year.
Insider Buying and Selling at Dorman Products
In other Dorman Products news, Director Steven L. Berman sold 2,669 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $112.57, for a total value of $300,449.33. Following the sale, the director now owns 876,156 shares in the company, valued at approximately $98,628,880.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Dorman Products news, Director Steven L. Berman sold 2,669 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $112.57, for a total transaction of $300,449.33. Following the transaction, the director now owns 876,156 shares of the company’s stock, valued at $98,628,880.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jeffery Darby sold 1,400 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $104.98, for a total value of $146,972.00. Following the transaction, the senior vice president now directly owns 23,671 shares in the company, valued at $2,484,981.58. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,297 shares of company stock worth $6,163,491. Corporate insiders own 10.00% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC increased its position in shares of Dorman Products by 5,460.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 278 shares of the auto parts company’s stock worth $31,000 after purchasing an additional 273 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Dorman Products during the 2nd quarter worth approximately $37,000. Covestor Ltd increased its position in shares of Dorman Products by 781.4% during the 3rd quarter. Covestor Ltd now owns 379 shares of the auto parts company’s stock worth $43,000 after purchasing an additional 336 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Dorman Products by 63.2% during the 3rd quarter. GAMMA Investing LLC now owns 483 shares of the auto parts company’s stock worth $55,000 after purchasing an additional 187 shares during the last quarter. Finally, USA Financial Formulas acquired a new position in shares of Dorman Products during the 3rd quarter worth approximately $58,000. Institutional investors and hedge funds own 84.70% of the company’s stock.
About Dorman Products
Dorman Products, Inc supplies replacement and upgrade parts for passenger cars, light trucks, medium- and heavy-duty trucks, utility terrain vehicles, and all-terrain vehicles in the motor vehicle aftermarket industry in the United States and internationally. It offers engine products, including intake and exhaust manifolds, fans, thermostat housings, and throttle bodies; undercar products comprising fluid lines, fluid reservoirs, connectors, 4-wheel drive components and axles, drain plugs, other engine, and transmission and axle components; steering and suspension products consist of control arms, ball joints, tie-rod ends, brake hardware and hydraulics, wheel and axle hardware, suspension arms, knuckles, links, bushings, and leaf springs, as well as other suspension, steering, and brake components; body products, such as door handles and hinges, window lift motors, window regulators, switches and handles, wiper components, lighting, electrical, and other interior and exterior vehicle body components, including windshields for UTVs; electronics products comprise new and remanufactured modules, clusters and sensors; and hardware products, such as threaded bolts and auto body fasteners, automotive and home electrical wiring components, and other hardware assortments and merchandise.
Recommended Stories
- Five stocks we like better than Dorman Products
- There Are Different Types of Stock To Invest In
- Intel: Is Now the Time to Be Brave?Â
- Investing in the High PE Growth Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Dorman Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dorman Products and related companies with MarketBeat.com's FREE daily email newsletter.